tbuckley/cabot-search huggingface dataset:
Structured handoff communication between affiliated health care sites.
Authors: Sara Helmig, Jonathan Burlison, Jennifer Morgan, Carolyn Russo
Journal: Journal of Clinical Oncology (2019)

182 Background: The affiliate program at St. Jude Children’s Research Hospital (St. Jude) allows more children access to pediatric oncology care closer to the patient’s home. Currently 8 clinics, located throughout the Southeast and the Midwest, are affiliated with St. Jude and contribute 35% of patients enrolled in St. Jude clinical trials. Handoffs and transitions of care are common weak points in health care provider communication as patients move between sites. Failures in communication led to inefficiencies in care, patient dissatisfaction, and near-miss events. Ensuring that the information exchanged during the patient transition is efficient and complete will benefit patient safety and trust. With no consistent pattern of communication between St. Jude and affiliate clinics, we aimed to develop and implement a standardized communication tool to be used with each patient transition between different health care sites. Methods: Each team of providers (St. Jude and affiliate clinics) created individual flow diagrams to define the current state of communication when patients were transitioning between remote sites. Using fishbone diagrams each team identified the barriers to effective communication. Common barriers were incomplete communication and synthesis by the receiver. Results: We developed a communication bundle. Using IPASS methodology (a communication bundle developed for inpatient handoffs between resident physicians) we designed a standardized mnemonic, SMART (S-summary of plan; M-medications/roadmap; A-action plan; R-return visit date; T-transfer confirmation) for a patient transition between different health care sites. The communication bundle was transmitted by secure email. The time to send or receive the communication bundle was &lt; 10 minutes. We measured % usage of the completed tool prior to transition, staff satisfaction, and number of errors. The SMART bundle was used 80% of the time and improved staff satisfaction. No errors have been identified. Conclusions: Closed loop, high-reliability communication can be accomplished between geographically remote health care sites using a standardized communication tool, which is transmitted electronically.
Correction: Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer
Authors: Neil E. Bhola, Valerie M. Jansen, Sangeeta Bafna, Jennifer M. Giltnane, Justin M. Balko, Mónica V. Estrada, Ingrid Meszoely, Ingrid Mayer, Vandana Abramson, Fei Ye, Melinda Sanders, Teresa C. Dugger, Eliezer V. Allen, Carlos L. Arteaga
Journal: Cancer Research (2019)
Changing treatment patterns in patients with stage IV non-small cell lung cancer (NSCLC) from United States community-based oncology practices.
Authors: Candice Yong, Brian Seal, Anna D. Coutinho, Orsolya Lunacsek, Bonnie B. Dean, Joanne P. Willey, Michael Eaddy, Ion Cotarla, Ranee Mehra
Journal: Journal of Clinical Oncology (2019)

13 Background: This study evaluated the shift in treatment patterns in Stage IV NSCLC following the approval of immune-oncology (IO) agents in the US. Methods: A retrospective cohort study was performed using structured data from a US community-based oncology electronic medical record (EMR) database for care received from Jan 2015-May 2018. The study sample included patients with Stage IV NSCLC, ≥18 years of age initiating first-line (1L) treatment with chemotherapy (chemo) or IO agents and classified into 3 groups: chemo alone, IO alone, or chemo+IO. Treatment patterns in 1L and treatment switch patterns in second-line (2L) are reported. A sub-group analysis of patients initiating 1L therapy during the last 6 months of the study period (Dec 2017-May 2018) was conducted to explore changes in 1L treatment patterns in the post-IO approval setting. Chart reviews were done for a subset of patients initiating 1L from Jan 2017-May 2018 to extract information on programmed cell death ligand 1 (PD-L1) testing and evaluate the association of PD-L1 expression levels with receipt of IO therapy. Results: Between Jan 2015-May 2018, 1,969 patients received 1L therapy with a chemo or IO agent. Mean age (SD) was 69.0 (10.1) years, with 44.7% female. The majority of patients (79%, n = 1570) initiated 1L therapy with chemo alone and 21% initiated IO (alone [14%, n = 271] or in combination with chemo [7%, n = 128]). Of 1L patients, 41% (n = 809) were treated with 2L therapy. Of the 1L chemo alone group, 37% (n = 580) received IO in 2L. The use of IO agents in 1L increased from 21% to 48% (n = 147) in the sub-group analysis of 305 patients initiating therapy Dec 2017-May 2018. In the subset of 62 patients whose charts were reviewed, 87% (n = 54) had their tumor tested for PD-L1, of which 37% (n = 20) had high (≥50%) expression values. The majority of high-PD-L1 patients were treated in 1L with IO alone (80%, n = 16), followed by chemo+IO (15%; n = 3), and only 5% (n = 1) received chemo alone. Conclusions: Initially, IO was used as 2L treatment for Stage IV NSCLC, but IO use shifted to 1L setting in the US by the end of 2017. The use of IO therapy alone or with chemotherapy in 1L was more likely in patients with ≥50% PD-L1 expression level.
A Phase 1 Trial of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) in Combination with Bortezomib in Patients with Relapsed/Refractory Mantle Cell Lymphoma.
Authors: Andre Goy, Peggy Ford, Tatyana Feldman, Andrew Pecora, Stuart Goldberg, Michele Donato, David Siegel, David Panush, Mark S. Berger
Journal: Blood (2007)
Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial
Authors: Giovanni L Ceresoli, Joachim G Aerts, Rafal Dziadziuszko, Rodryg Ramlau, Susana Cedres, Jan P van Meerbeeck, Manlio Mencoboni, David Planchard, Antonio Chella, Lucio Crinò, Maciej Krzakowski, Jörn Rüssel, Antonio Maconi, Letizia Gianoncelli, Federica Grosso
Journal: The Lancet Oncology (2019)
Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Rigosertib in a Phase I-II Study
Authors: John Roboz, Shyamala C. Navada, Sool Yeon Cho, Michael E. Petrone, Steven M. Fruchtman, Lewis R. Silverman
Journal: Blood (2018)
Results of the lung and colorectal cancer screening study in China: a feasibility, randomised controlled trial
Authors: Jiang Li, Ping Hu, Jufang Shi, Martina Taylor, Ni Li, Jiansong Ren, Hongda Chen, Xianzhen Liao, Yuqin Liu, Lingbin Du, Paul Pinsky, Philip Prorok, Richard Fagerstrom, Barnett Kramer, Min Dai, Jie He
Journal: The Lancet (2019)
Abstract 854: The Role of Mitochondrial Permeability Transition in the Regulation of ETC Supercomplexes Assembly by OPA1
Authors: Sehwan Jang
Journal: Circulation Research (2019)

Optic atrophy type 1 (OPA1), a dynamin-related GTPase is the inner mitochondrial membrane (IMM) protein, which, in addition to mitochondrial fusion, participates in maintaining the structural integrity of the IMM. The function and topography of the IMM is also regulated by changes in the matrix volume. Opening of the mitochondrial permeability transition pores (PTP) is the leading cause of mitochondrial matrix swelling. However, the cause-and-effect relationship between OPA1 proteolytic cleavage and PTP induction remains unknown. Here, we elucidated the role of PTP in OPA1-mediated regulation of electron transport chain (ETC) supercomplexes (SCs) assembly. First, intact mitochondria isolated from the rat heart were used to analyze the effect of PTP induction on the cleavage of long (L)-OPA1. Calcium-induced mitochondrial swelling increased L-OPA1 cleavage (66%, P&lt;0.001) associated with accumulation of short (S)-OPA1. Inhibition of swelling by sanglifehrin A (a PTP inhibitor) prevented L-OPA cleavage whereas tert-butyl hydroperoxide (TBH) had no effect on L-OPA levels. Second, OPA1 knockdown (KD) by siRNA in HEK cells resulted in a 74% decrease (P&lt;0.001) in OPA1 protein expression but did not change the proportion of L-OPA1 to total OPA. Mitochondria isolated from OPA1 KD cells showed reduced calcium-stimulated swelling with no changes in protein levels of cyclophilin D, a major PTP regulator. OPA1 KD cells demonstrated a 20% increase (P&lt;0.05) in calcium-induced ROS generation. Analysis of individual ETC complexes revealed significant reduction of protein levels of the complexes I, III, and IV in OPA1 KD cells. Likewise, activities of complexes I and IV were reduced (48% and 37%, respectively, P&lt;0.01 for both). OPA1 KD cells contained 38% (P&lt;0.05) less ATP whereas the citrate synthase activity reflecting mitochondria mass was not affected. Blue native PAGE analysis demonstrated a 35% decrease (P&lt;0.01) of high molecular weight proteins (&gt;100 kDa) and a 24% decrease (P&lt;0.05) of the respirasome, the main SC, levels in OPA1 KD mitochondria. We conclude that mitochondrial swelling by PTP opening stimulates OPA1 cleavage, and reduced OPA1 levels result in cristae malformation including reduced respirasome levels and the ETC complexes activity.
Frontline Treatment with Dasatinib in Very Elderly Patients (&gt; 75 Years) with Chronic Myeloid Leukemia: Is It Feasible?
Authors: Roberto Latagliata, Fabio Stagno, Mario Annunziata, Malgorzata Monika Trawinska, Alessandra Iurlo, Nicola Sgherza, Carmen Fava, Antonella Gozzini, Luigiana Luciano, Massimiliano Bonifacio, Federica Sorà, Sabrina Crescenzi Leonetti, Monica Crugnola, Gabriele Gugliotta, Sara Galimberti, Nicola Orofino, Elena Mariggiò, Costanzo Feo, Mario Tiribelli, Endri Mauro, Antonella Russo Rossi, Attilio Guarini, Elisabetta Abruzzese, Paolo Vigneri, Gianantonio Rosti, Massimo Breccia
Journal: Blood (2018)
Abstract 17547: Hypochloremia Predicts Poor Clinical Outcome in Patients With Acute Decompensated Heart Failure Irrespective of Left Ventricular Ejection Fraction
Authors: Jun Nakamura, Takahihisa Yamada, Takashi Morita, Yoshio Furukawa, Shunsuke Tamaki, Yusuke Iwasaki, Masato Kawasaki, Atsushi Kikuchi, Tsutomu Kawai, Masahiro Seo, Iyo Ikeda, Eiji Fukuhara, Makoto Abe, Kiyomi Kayama, Masatsugu Kawahira, Kazuya Tanabe, Masatake Fukunami
Journal: Circulation (2017)

Background: Electrolyte abnormalities such as hyponatremia and hypochloremia are prevalent in patients(pts) with acute decompensated heart failure (ADHF). Although hyponatremia is well-established ...
Behavioral Patterns and the Role of Ethnicity in Patient Awareness of Multiple Myeloma and the Psychophysical Impact of Its Treatment
Authors: Pooja Advani, Abhisek Swaika, Denice D. Tsao-Wei, Ahsan Alamgir, Brian Chung, Christine Duran, Susan Groshen, Savrina Bola, Asher Chanan-Khan, Sikander Ailawadhi
Journal: Blood (2014)
Wnt5a Induces Association of ROR1 with Ca2+/Calmodulin-Dependent Protein Kinase II and ROR1-Dependent Calcium Influx in Chronic Lymphocytic Leukemia
Authors: Liguang Chen, Yun Chen, Jian Yu, Ling Zhang, Laura Z. Rassenti, Thomas J. Kipps
Journal: Blood (2018)
Efficacy and Safety of Histone Deacetylase Inhibitors in Multiple Myeloma - a Systematic Review of Early Phase Clinical Trials
Authors: Sharoon Samuel, Muhammad Junaid Tariq, Muhammad Usman, Amna Khalid, Muhammad Asad Fraz, Awais Ijaz, Faiza Jamil, Muhammad Yasir, Malik Qistas Ahmad, Muhammad Jahanzeb Khalil, Shehroz Aslam, Madeeha Shafqat, Ceren Durer, Zunairah Shah, Faiz Anwer
Journal: Blood (2018)
The Comparison of Melphalan Administration on Day 3 with Administration on Day 1 on Neutrophil and Platelet Engraftment in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Authors: Ali Unal, Leylagül Kaynar, Esra Yıldızhan, Nermin Keni, Zeynep Güven, Bulent Eser, Mustafa Cetin
Journal: Blood (2018)
Can we identify a group of breast cancer patients with a good prognosis despite four or more positive (4+) axillary nodes using a tissue microarray (TMA)?
Authors: S. J. Crabb, C. D. Bajdik, C. H. Speers, D. G. Huntsman, K. A. Gelmon
Journal: Journal of Clinical Oncology (2007)

10582 Background: Although breast cancer with 4+ axillary lymph nodes generally carries a poor prognosis, we hypothesized that a good prognostic subgroup of such patients would be identifiable by immunohistochemical (IHC) biomarkers. Methods: Patients with primary breast cancer with 4+ axillary nodes and no metastatic disease at diagnosis were identified from a large clinically annotated TMA of formalin-fixed paraffin-embedded archival breast cancers and analyzed for eight IHC based biomarkers: estrogen receptor, HER2, carbonic anhydrase IX, EGFR, CK 5/6, progesterone receptor, p53 and Ki67. Expression of each biomarker was scored 0 or 1 to indicate good or bad prognosis based on univariate analysis of relapse free survival (RFS). Patients were banded as having a total score of 0 (i.e. each biomarker predicted a good outcome), 1–4 or 5–8. Kaplan Meier and Cox regression analysis of RFS outcomes was performed. 10 year RFS for each band was compared to the mean of predicted outcomes based on the prognostic tool Adjuvant! ( www.adjuvantonline.com ). Results: 313 eligible patients were identified and complete data were available for 228. The subset of 228 was similar to the larger group of 313 with respect to RFS and conventional prognostic factors. 10 year RFS for the 228 patients was 39.5% (standard error, SE 3.4%). The subgroup of 37 (16%) scoring zero for all 8 biomarkers had a mean 10 year RFS of 77.6% (SE 7.0). Mean 10 year RFS for the bands scoring 1–4 (154 patients, 68%) and 5–8 (37 patients, 16%) were 34.9% (SE 4.1) and 19.0% (SE 6.9) respectively. Mean 10 year RFS predictions by Adjuvant! were 35.9% (SE 2.6), 34.5% (SE 1.2) and 34.3% (SE 2.3) respectively. In multivariate analysis with conventional prognostic factors, the banded biomarker score retained statistical significance for predicting RFS (p=0.0007) along with estrogen receptor status (p=0.03) and tumour size (p=0.01). Conclusions: This TMA biomarker panel identified a breast cancer subgroup with good prognosis despite extensive axillary node involvement. Long term outcome was markedly better than that predicted by conventional prognostic factors. If validated, treatment decisions and clinical trial stratification might be modified using this new score. No significant financial relationships to disclose.
Abstract 823: The Extracellular Matrix Component, Hyaluronan, Provokes a Pro-Inflammatory Phenotype in Macrophages
Authors: Timothy N Audam, Sujith Dassanayaka, Andrea Jurkovic, Bethany Long, Kenneth R Brittian, Marcin Wysoczynski, Steven P Jones
Journal: Circulation Research (2019)

Background: The extracellular matrix (ECM) provides structural and functional support for the myocardium, but myocardial infarction (MI) changes the composition of the ECM. One of the chief components of the ECM, hyaluronan (HA), is elevated after MI; however, specific biological actions of HA—particularly at the level of infiltrating immune cells and implications of such interactions on ventricular remodeling—have not been explored. Goals: Because upregulation of HA coincides with macrophage infiltration after MI, we determined whether hyaluronan interacts with macrophages and investigated the implication of such interactions on macrophage function. Methods: WT mice were subjected to non-reperfused MI to determine changes in hyaluronan synthases (HAS), hyaluronidases (HYAL), and HA levels in the heart. Interaction of HA with macrophages was studied by polarizing bone marrow derived macrophages and analyzing cells by flow cytometry. Next, we characterized the ability of macrophages to metabolize HA by profiling polarized macrophages for HA-metabolizing enzymes, HA receptors, HA-binding proteins, hyaluronidase activity, and phagocytosis. Results: Compared to Sham hearts, MI (n=5/group) augmented the expression of HAS-2 (10-fold, p=0.002) and HYAL-2 (2 to 4-fold, p=0.0004) in the infarct and remote regions of the heart at 5 d post-MI. HA levels (n=8/group) were elevated in the infarct (1 to 2-fold, p=0.0200) and remote (2 to 3-fold, p=0.0007) regions of the heart compared to sham hearts. Polarizing macrophages (n=3/group) in the presence fluorescein-conjugated HA (HA-FL) showed that naïve (M0), pro-inflammatory (M1), and pro-resolving (M2) macrophages interact with HA-FL; M1 showed the highest FITC intensity. Interestingly, exposing macrophages (n=5/group) to HA provoked an inflammatory phenotype, as reflected by enhanced expression of TNFα (4-fold, p=0.0001) and IL-1β (7-fold, p=0.0094) mRNA; HA also enhanced macrophage phagocytosis (0.5-fold, p= 0.0476). Conclusion: Hyaluronan is elevated following MI and can influence macrophage function. Because of the accumulation of hyaluronan and macrophages in the post-MI heart, macrophage-hyaluronan interactions may be a nexus regulating ventricular remodeling.
Hypertrophic Cardiomyopathy–Related Sudden Cardiac Death in Young People in Ontario
Authors: Adaya Weissler-Snir, Katherine Allan, Kristopher Cunningham, Kim A. Connelly, Douglas S. Lee, Danna A. Spears, Harry Rakowski, Paul Dorian
Journal: Circulation (2019)

Hypertrophic cardiomyopathy (HCM) is considered a leading cause of sudden cardiac death (SCD) in younger people. The incidence of HCM-related SCD and its relationship to exercise have not been well studied in large comprehensive studies outside of tertiary care settings. This study sought to estimate the incidence of HCM-related SCD and its association with exercise in a large unselected population.Using the Office of the Chief Coroner of Ontario database encompassing all deaths attended by the coroner, we identified all HCM-related SCDs in individuals 10 to 45 years of age between 2005 and 2016 (70 million person-years). Confirmation of HCM was based on typical macroscopic and microscopic features (definite HCM-related SCD). Sudden deaths with a prior clinical diagnosis of HCM but no autopsy were considered probable HCM-related SCDs. Cases with typical features but no myofiber disarray were considered possible HCM. The completeness of data was verified in a subset of patients in the Toronto area with the use of a registry of all emergency medical services-attended cardiac arrests, with an autopsy rate of 94%. To estimate the number of HCM-related aborted cardiac arrests and lives potentially saved by implantable cardioverter-defibrillators, all de novo implantations for secondary prevention and all implantations and appropriate shocks for primary prevention in patients with HCM 10 to 45 years of age, respectively, were identified with the use of a registry containing data on implantable cardioverter-defibrillator implantations from all implanting sites throughout Ontario.Forty-four, 3, and 6 cases of definite, probable, and possible HCM-related SCDs, respectively, were identified, corresponding to estimated annual incidence rates of 0.31 per 1000 HCM person-years (95% CI, 0.24-0.44) for definite HCM-related SCD, 0.33 per 1000 HCM person-years (95% CI, 0.34-0.62) for definite or probable HCM-related SCD, and 0.39 per 1000 HCM person-years (95% CI, 0.28-0.49) for definite, probable, or possible HCM-related SCD (estimated 140 740 HCM person-years of observation). The estimated annual incidence rate for HCM-related SCD plus aborted cardiac arrest and HCM-related life-threatening arrhythmia (SCD, aborted cardiac arrest, and appropriate implantable cardioverter-defibrillator shocks) was 0.84 per 1000 HCM person-years (95% CI, 0.70-1.0). The majority (70%) of SCDs occurred in previously undiagnosed individuals. Most SCDs occurred during rest (64.8%) or light activity (18.5%).The incidence of HCM-related SCD in the general population 10 to 45 years of age is substantially lower than previously reported, with most cases occurring in previously undiagnosed individuals. SCDs are infrequently related to exercise.
Impairment of the Stromal SDF-1-Mediated Hematopoietic Support By GDF-11 in MDS Is Rescued By Luspatercept
Authors: Manja Wobus, Anna Mies, Nandini Asokan, Uta Oelschlaegel, Susann Winter, Martina Rauner, Lorenz Hofbauer, Martin Bornhäuser, Uwe Platzbecker
Journal: Blood (2018)
High Incidence but Very Low Mortality of Epstein Barr Virus Related Post-Transplantation Lymphoproliferative Disorder after T-Cell Replete Haploidentical Peripheral Blood Stem Cell Transplantation
Authors: Queralt Salas Gay, Zeyad Al-Shaibani, Wilson Lam, Fotios V. Michelis, Santhosh Thyagu, Dennis Dong Hwan Kim, Jeff H. Lipton, Rajat Kumar, Auro Viswabandya, Arjun Law
Journal: Blood (2018)
Monitoring of Wilms' Tumor Gene 1 Levels Predict Early Relapse After Allogeneic Hematopoietic Stem Cells Transplantation in Patients with High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome,
Authors: Elisa Sala, Carlo Messina, Cristina Tresoldi, Matteo Carrabba, Michela Tassara, Alessandro Crotta, Alessandro Vignati, Elena Guggiari, Roberta Mattarucchi, Andrea Assanelli, Jacopo Peccatori, Consuelo Corti, Fabio Ciceri, Massimo Bernardi
Journal: Blood (2011)
Immunoglobulin Heavy Chain (IgH) Knockout Inhibits Proliferation of Pre-BCR+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) Via a FOXO1 and MYC Dependent Mechanism
Authors: Stefan Koehrer, Ondrej Havranek, R Eric Davis, Felix Seyfried, Greg Coffey, Ekaterina Kim, Nathalie Y. Rosin, Elisa ten Hacken, Ulrich Jäger, Katrina Vanura, Susan O'Brien, Deborah A. Thomas, Hagop M. Kantarjian, Dipanjan Ghosh, Zhiqiang Wang, Lüder Hinrich Meyer, Hassan Jumaa, Jan A. Burger
Journal: Blood (2014)
Nearly a Third of Clonal Hematopoiesis-Associated DNMT3A Mutations Reduce Protein Stability and May be Associated with Poorer Prognosis
Authors: Yung-Hsin Huang, Ayala Tovy, Venkatasubramaniam Sundaramurthy, Jianzhong Su, Joanne Hsu, Lian He, Anna Guzman, Yubin Zhou, Alexander Meissner, Wei Li, Margaret A. Goodell
Journal: Blood (2018)
Comparison Of Conventional, FISH and GEP Prognostic Factors In Multiple Myeloma: Introducing a Novel Risk Stratification
Authors: Rowan Kuiper, Martin van Vliet, Annemiek Broyl, Yvonne de Knegt, Bronno van der Holt, Laila el Jarari, George Mulligan, Walter Gregory, Gareth J Morgan, Hartmut Goldschmidt, Uta Bertsch, Henk Lokhorst, Mark van Duin, Erik van Beers, Pieter Sonneveld
Journal: Blood (2013)